



# ***Alpa Laboratories Ltd.***

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

13<sup>th</sup> November, 2021

To,  
Listing Department,  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001  
Scrip Code: 532878

To,  
Listing Department,  
National Stock Exchange of India Limited.  
'Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Scrip Code: ALPA

**Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

This is with reference to our letter dated 02<sup>nd</sup> November, 2021 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter and Half Year ended on 30<sup>th</sup> September, 2021 with Limited Review Report from the Statutory Auditor of the Company.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

**For ALPA LABORATORIES LIMITED**

**Swati Bagh**  
Company Secretary  
Membership No.53536



# Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

Anuradha Ratnaparkhi

FCA, M.com.



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, Indore 452 016 (M.P.)  
Tel. : +91 731-4979244, M : +91 98934-62644  
E-mail : aratnaparkhi@hotmail.com

## INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015 (AS AMENDED)

To the Board of Directors of **ALPA LABORATORIES LIMITED**,

1. I have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **30<sup>th</sup> September, 2021**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles accepted in India. My responsibility is to express a conclusion on the Statement based on my review.
3. I conducted my review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.
4. Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Anuradha Ratnaparkhi & Associates.**

Chartered Accountants

Firm Registration No.023451C

Anuradha Ratnaparkhi

Proprietor

Membership Number: 075412

UDIN: 21075412AAAAAT7821



Date: 13<sup>th</sup> Day of November, 2021

Place: Indore

**ALPA LABORATORIES LIMITED**

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2021

(Rs. in lacs except EPS)

**I. Statement of Profit and Loss - Standalone and Consolidated**

Particular	Standalone Results					
	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2,625.50	3,151.94	2,310.79	5,777.44	3,940.25	9,755.42
b) Other Income	269.78	426.10	86.65	695.88	259.15	441.07
<b>1. Total income from operations (net) (a+b)</b>	<b>2,895.29</b>	<b>3,578.04</b>	<b>2,397.44</b>	<b>6,473.33</b>	<b>4,199.40</b>	<b>10,196.49</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,745.83	1,740.32	1,671.03	3,486.15	2,440.91	5,422.74
b) Purchases of stock-in-trade	136.00	161.01	215.09	297.01	280.15	639.12
c) Changes in inventories of finished products, work in progress and stock in trade	(293.68)	252.49	(432.27)	(41.19)	(384.07)	(115.29)
d) Employee benefit expenses	288.25	288.00	277.65	576.25	526.69	1,174.51
e) Finance costs	6.03	4.45	3.49	10.48	5.77	9.82
f) Depreciation and amortization expenses	42.01	30.59	28.97	72.60	57.08	122.87
g) Other expenses						
Manufacturing & Operating	174.54	128.06	138.14	302.60	218.94	528.98
Others	221.69	328.18	266.53	549.87	502.10	1,334.51
<b>Total expenses</b>	<b>2,320.66</b>	<b>2,933.10</b>	<b>2,168.63</b>	<b>5,253.76</b>	<b>3,647.57</b>	<b>9,117.26</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>574.62</b>	<b>644.94</b>	<b>228.81</b>	<b>1,219.56</b>	<b>551.83</b>	<b>1,079.23</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>574.62</b>	<b>644.94</b>	<b>228.81</b>	<b>1,219.56</b>	<b>551.83</b>	<b>1,079.23</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	(250.00)
Deffered tax	-	-	-	-	-	114.19
Tax Related to Earlier Years	-	-	-	-	-	11.40
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>574.62</b>	<b>644.94</b>	<b>228.81</b>	<b>1,219.56</b>	<b>551.83</b>	<b>726.44</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	0.08	0.49	0.54	0.57	1.04	2.17
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	<b>0.08</b>	<b>0.49</b>	<b>0.54</b>	<b>0.57</b>	<b>1.04</b>	<b>2.17</b>
<b>9. Total comprehensive income for the period (7+8)</b>	<b>574.70</b>	<b>645.43</b>	<b>229.35</b>	<b>1,220.13</b>	<b>552.87</b>	<b>728.61</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity ( excluding revaluation reserve)</b>	-	-	-	-	-	9,647.51
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>2.73</b>	<b>3.07</b>	<b>1.09</b>	<b>5.80</b>	<b>2.63</b>	<b>3.46</b>



For ALPA LABORATORIES LIMITED  
*Mahendra*  
 MAHENDRA SINGH CHAWLA  
 DIRECTOR  
 DIN NO. 00362058



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015 (AS AMENDED)**

To the Board of Directors of **ALPA LABORATORIES LIMITED**,

1. I have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** (The Holding Company) and its Subsidiary (refer Annexure1 for the list of subsidiary included in the Statement) for the quarter **ended 30<sup>th</sup> September, 2021**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles accepted in India. My responsibility is to express a conclusion on the Statement based on my review.
3. I conducted my review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.

I also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations (As amended), to the extent applicable.

4. Based on my review conducted, nothing has come to my attention that causes me to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.



# Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

Anuradha Ratnaparkhi

FCA, M.com.



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, Indore 452 016 (M.P.)  
Tel. : +91 731-4979244, M : +91 98934-62644  
E-mail : aratnaparkhi@hotmail.com

5. The consolidated unaudited quarterly financial results also include the subsidiary's share of net Loss (including other comprehensive income) (before eliminating intercompany transactions) amounting to ₹354 for the quarter ended 30<sup>th</sup> September, 2021, as considered in the consolidated financial results, whose financial information has not been audited by me. These financial information are unaudited and have been furnished to me by the management duly certified by them and my opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this associate, and my report in terms of Regulation 33 read with Regulation 63 of the SEBI {Listing Obligations and Disclosure Requirements} Regulations, 2015, read with SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, in so far as it relates to the aforesaid subsidiary, are based solely on such unaudited financial information. In my opinion and according to the information and explanations given to me by the management these financial information are not material to the Group.

My opinion on the consolidated financial results is not modified in respect of this matter with respect to my reliance on the financial information certified by the management.

**For Anuradha Ratnaparkhi & Associates.**

Chartered Accountants


Firm Registration No.023451C

**Anuradha Ratnaparkhi**

Proprietor

Membership Number: 075412

UDIN: 21075412AAAAAU7433



Date: 13<sup>th</sup> Day of November, 2021

Place: Indore

# Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

**Anuradha Ratnaparkhi**

FCA, M.com.



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, Indore 452 016 (M.P.)  
Tel. : +91 731-4979244, M : +91 98934-62644  
E-mail : aratnaparkhi@hotmail.com

## Annexure 1

List of entities included in the statement:

I) Susidiary:

1. Norfolk Mercantile Private Limited



# ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2021

(Rs. in lacs except EPS)

Particular	Consolidated Results					
	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2,625.50	3,151.94	2,351.28	5,777.44	4,367.99	8,596.91
b) Other Income	266.84	426.86	26.72	693.70	97.30	291.24
<b>1. Total income from operations (net) (a+b)</b>	<b>2,892.35</b>	<b>3,578.80</b>	<b>2,377.99</b>	<b>6,471.15</b>	<b>4,465.28</b>	<b>8,888.15</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,745.83	1,740.32	1,494.56	3,486.15	2,815.45	4,948.01
b) Purchases of stock-in-trade	136.00	161.01	44.21	297.01	94.41	193.83
c) Changes in inventories of finished products, work in progress and stock in trade	(293.68)	252.49	19.47	(41.19)	(101.80)	(42.41)
d) Employee benefit expenses	288.25	288.00	279.69	576.25	561.03	1,182.43
e) Finance costs	6.20	4.28	4.49	10.48	13.45	19.62
f) Depreciation and amortization expenses	42.01	30.59	77.82	72.60	153.48	316.45
g) Other expenses						
Manufacturing & Operating	174.54	128.06	116.30	302.60	215.12	427.09
Others	221.69	328.19	302.81	549.88	554.26	1,552.38
<b>Total expenses</b>	<b>2,320.83</b>	<b>2,932.94</b>	<b>2,339.35</b>	<b>5,253.77</b>	<b>4,305.40</b>	<b>8,597.40</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>571.52</b>	<b>645.86</b>	<b>38.65</b>	<b>1,217.38</b>	<b>159.89</b>	<b>290.75</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>571.52</b>	<b>645.86</b>	<b>38.65</b>	<b>1,217.38</b>	<b>159.89</b>	<b>290.75</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	(190.00)
Deferred tax	-	-	-	-	-	75.48
Tax Related to Earlier Years	0.15	-	-	0.15	-	9.11
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>571.66</b>	<b>645.86</b>	<b>38.65</b>	<b>1,217.52</b>	<b>159.89</b>	<b>185.34</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	1.68	(1.11)	0.30	0.57	1.67	2.49
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	<b>1.68</b>	<b>(1.11)</b>	<b>0.30</b>	<b>0.57</b>	<b>1.67</b>	<b>2.49</b>
<b>9. Total comprehensive income for the period (7+8)</b>	<b>573.34</b>	<b>644.75</b>	<b>38.95</b>	<b>1,218.09</b>	<b>161.56</b>	<b>187.82</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity (excluding revaluation reserve)</b>	-	-	-	-	-	8,660.08
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>2.72</b>	<b>3.06</b>	<b>0.19</b>	<b>5.79</b>	<b>0.77</b>	<b>0.89</b>

**Notes -**

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules, 2015 and Companies ( Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- In March, 2020 the World Health Organization (WHO) declared COVID-19 a Global Pandemic. Consequent to this nationwide lockdown was declared on 24th March, 2020 by Government of India and statewide lockdown was declared in April, 2021 by Government of Madhya Pradesh. The Company has assessed the possibility of any impact of COVID-19 on its financial statements based on the internal and external information available up to the date of approval of these financial statements and concluded that no adjustment is required. Further, the Company do not anticipate any challenges in its ability to continue as going concern or meeting its financial obligations.



For ALPA LABORATORIES LIMITED

*Mahendra Singh Chawla*  
**MAHENDRA SINGH CHAWLA**  
 DIRECTOR  
 DIN NO.00362058

**ALPA LABORATORIES LIMITED**

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2021

(Rs. in lacs except EPS)

**II. Statement of Assets and Liabilities - Standalone and Consolidated**

Particulars	Standalone Results		Consolidated Results	
	30-Sep-21	31-Mar-21	30-Sep-21	31-Mar-21
	Unaudited	Audited	Unaudited	Audited
<b>ASSETS</b>				
<b>Non-current assets</b>				
(a) Property Plant and Equipment	886.56	715.65	886.56	715.65
(b) Capital Work-in-progress	-	157.47	-	157.47
(c) Investments in subsidiaries, associates and joint venture	1,110.62	1,108.27	-	-
(d) Intangible Assets	4.90	5.51	4.90	5.51
(e) Financial Assets				
(i) Investment	735.82	1,015.32	735.82	1,015.32
(ii) Other Financial Assets	34.45	33.86	34.45	33.86
(f) Deferred tax assets (net)	-	-	-	-
<b>Sub-total - Non-current assets</b>	<b>2,772.35</b>	<b>3,036.08</b>	<b>1,661.72</b>	<b>1,927.81</b>
<b>Current Assets</b>				
(a) Inventories	1,886.19	1,655.98	1,886.19	1,655.98
(b) Financial Assets				
(i) Investment	5,600.46	4,068.96	5,600.46	4,068.96
(ii) Trade receivables	3,360.33	3,543.01	3,360.33	3,543.01
(iii) Cash and Cash Equivalents	384.42	152.46	387.16	180.20
(iv) Bank Balances other than (iii) above	154.00	871.10	154.00	871.10
(v) Short term loans & advances	5.53	4.23	99.44	77.32
(vi) Others	190.00	634.92	190.00	634.91
(c) Current Tax Assets (Net)	-	-	-	-
(d) Other current assets	1,227.16	1,056.73	1,227.16	1,077.55
<b>Sub-total - Current assets</b>	<b>12,808.09</b>	<b>11,987.39</b>	<b>12,904.73</b>	<b>12,109.03</b>
<b>TOTAL - ASSETS</b>	<b>15,580.43</b>	<b>15,023.47</b>	<b>14,566.45</b>	<b>14,036.84</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
(a) Equity Share capital	2,104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	10,867.64	9,647.52	9,877.85	8,660.08
<b>Sub-total - Equity</b>	<b>12,971.70</b>	<b>11,751.58</b>	<b>11,981.91</b>	<b>10,764.14</b>
<b>Liabilities</b>				
<b>Non-current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	25.00	0.91	-	0.91
<b>Sub-total - Non-current liabilities</b>	<b>25.00</b>	<b>0.91</b>	<b>-</b>	<b>0.91</b>
<b>Deferred Tax Liability</b>	<b>21.60</b>	<b>21.60</b>	<b>21.60</b>	<b>21.60</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	554.01	-	554.01	-
(ii) Trade Payables	1,645.61	2,472.45	1,645.61	2,473.10
(iii) Other Financial Liabilities	93.20	141.93	93.20	141.93
(b) Provisions	185.96	168.11	186.12	168.27
(c) Current tax Liabilities (Net)		438.39		438.39
(d) Other Current Liabilities	83.34	28.50	84.00	28.50
<b>Sub-total - Current liabilities</b>	<b>2,583.73</b>	<b>3,270.98</b>	<b>2,584.55</b>	<b>3,271.79</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>15,580.43</b>	<b>15,023.47</b>	<b>14,566.45</b>	<b>14,036.84</b>



For ALPA LABORATORIES LIMITED

*Mahendra*

MAHENDRA SINGH CHAWLA

DIRECTOR

DIN NO.00362058



**ALPA LABORATORIES LIMITED**

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 30th September 2021

(Rs. in lacs except EPS)

**III. Statement of Cash Flows - Standalone and Consolidated**

Particular	For the Half Year Ended on 30-09-2021	
	Standalone	Consolidated
<b><u>CASH FLOW FROM OPERATING ACTIVITIES:</u></b>		
Profit / (loss) before tax	1,219.56	1,217.38
Adjustments for:		
Depreciation and amortization	72.60	72.60
Finance cost	10.48	10.48
Dividend income	(6.93)	(6.93)
Interest income	(51.27)	(51.27)
Net (Gain)/Loss on sale / fair valuation of investments through profit and loss	(619.96)	(619.96)
Bad debts / assets written off	58.76	58.76
Other Comprehensive Income (Non Cash)		
(Profit)/ loss on sale of Fixed Assets (net)		
<b>Operating profit before working capital changes</b>	<b>683.23</b>	<b>681.04</b>
Changes in Operating assets and liabilities:		
Decrease/ (Increase) in Trade Receivable/Other Receivables	396.53	299.13
Decrease/ (Increase) in Inventories	(230.21)	(230.21)
Increase/ (Decrease) in Provisions	17.85	17.85
Increase/ (Decrease) in Trade payable/Current Liabilities	(820.72)	(820.72)
<b>Net Cash Flow from Operating Activities</b>	<b>46.68</b>	<b>(52.90)</b>
Income taxes paid		
<b>Net Cash Flow from Operating Activities Before Exceptional Items</b>	<b>46.68</b>	<b>(52.90)</b>
Exceptional Items		
<b>Net Cash Flow from Operating Activities After Exceptional Items (I)</b>	<b>46.68</b>	<b>(52.90)</b>
<b><u>CASH FLOW FROM INVESTING ACTIVITIES:</u></b>		
Proceeds from/(Payments for):		
Dividend received from others	6.93	6.93
Interest Received	51.27	51.27
Property, plant and equipment	(86.04)	(144.18)
Purchase of investment	(1,073.96)	(913.89)
Investment in subsidiaries/ Joint Venture	2.35	
<b>Net Cash Flow from Investing Activities (II)</b>	<b>(1,099.45)</b>	<b>(999.87)</b>
<b><u>CASH FLOW FROM FINANCING ACTIVITIES:</u></b>		
Proceeds from/(payment to):		
Long Term Borrowings	24.09	(0.91)
Short Term Borrowings	554.01	554.01
Interest Paid	(10.48)	(10.48)
<b>Net Cash Flow from Financing Activities (III)</b>	<b>567.63</b>	<b>542.63</b>
<b>Net Increase/(Decrease) In Cash and Cash Equivalents (I + II + III)</b>	<b>(485.14)</b>	<b>(510.15)</b>
<b>Cash and Cash Equivalents as at the beginning of the year</b>	<b>1,023.56</b>	<b>1,051.30</b>
<b>Cash and Cash Equivalents as at the end of the year</b>	<b>538.42</b>	<b>541.15</b>
Cash and Cash Equivalents Comprise of:		
Cash and Bank Balances	384.42	387.16
Fixed Deposits with Banks	154.00	154.00
<b>Total Cash &amp; Cash Equivalents</b>	<b>538.42</b>	<b>541.16</b>



For ALPA LABORATORIES LIMITED  
*Mahendra*  
**MAHENDRA SINGH CHAWLA**  
 DIRECTOR  
 DIN NO.00362058